These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18477034)

  • 1. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
    Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
    Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
    Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
    Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
    Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
    Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib (BAY 43-9006): review of clinical development.
    Ng R; Chen EX
    Curr Clin Pharmacol; 2006 Sep; 1(3):223-8. PubMed ID: 18666747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
    Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
    Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
    Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
    Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
    Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in advanced clear-cell renal-cell carcinoma.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
    N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
    J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
    Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
    Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
    Mross K; Steinbild S; Baas F; Gmehling D; Radtke M; Voliotis D; Brendel E; Christensen O; Unger C
    Eur J Cancer; 2007 Jan; 43(1):55-63. PubMed ID: 17095207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum pancreatic enzyme elevation under treatment with sorafenib].
    Hyodo I; Adachi M; Tsukamoto T; Murai M; Naito S; Akaza H
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1651-6. PubMed ID: 23152014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Nabors LB; Supko JG; Rosenfeld M; Chamberlain M; Phuphanich S; Batchelor T; Desideri S; Ye X; Wright J; Gujar S; Grossman SA;
    Neuro Oncol; 2011 Dec; 13(12):1324-30. PubMed ID: 21954442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
    Sridhar SS; Winquist E; Eisen A; Hotte SJ; McWhirter E; Tannock IF; Mukherjee SD; Wang L; Blattler C; Wright JJ; Moore MJ
    Invest New Drugs; 2011 Oct; 29(5):1045-9. PubMed ID: 20191303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.